Fulltext present in this item

Thumbnail
Fulltext: 177846.pdf
Format: PDF
Description: preprint version
Title: Novel Insights into Membrane Targeting of B Cell Lymphoma
Author(s): Winde, C.M. de; Elfrink, S.; Spriel, A.B. van
Publication year: 2017
Source: Trends in Cancer, vol. 3, iss. 6, (2017), pp. 442-453
ISSN: 2405-8025
DOI: https://doi.org/10.1016/j.trecan.2017.04.006
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/177846   https://hdl.handle.net/2066/177846

Display more details
Subject: Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences
Organization: Tumorimmunology
Journal title:
Trends in Cancer
Volume: vol. 3
Issue: iss. 6
Page start: p. 442
Page end: p. 453
Abstract:
Standard therapy of patients with B cell non-Hodgkin lymphoma (B-NHL) predominantly consists of chemotherapy combined with anti-CD20 (e.g., rituximab) immunotherapy. However, relapse of aggressive B-NHL occurs frequently, and this may coincide with therapy resistance. This demonstrates the urgent need for exploring new lymphoma-targeted therapies. We review here recent insights in the pathophysiology of B-NHL and discuss CD20 and three alternative membrane targets (B cell receptor, immune checkpoints PD-1/PD-L1, tetraspanin CD37) that are currently in the spotlight for B-NHL treatment. Furthermore, we present a novel concept in which the plasma membrane organization of the lymphoma B cell determines the efficacy of membrane-targeted therapies, and this has consequences for treatment application and clinical outcome in patients with B cell lymphoma.

This item appears in the following Collection(s)

Browse

Statistics